APA (7th ed.) Citation

AJ, S., H, X., S, G., I, N., P, R., D, H., & L, H. (2019). Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: Comparison between European and non-European population. Dove Medical Press.

Chicago Style (17th ed.) Citation

AJ, Savitz, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, and Hargarter L. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.

MLA (8th ed.) Citation

AJ, Savitz, et al. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.